Last reviewed · How we verify
Cellular and tissue based products
This drug stimulates cellular and tissue repair.
This drug stimulates cellular and tissue repair. Used for Treatment of chronic wounds.
At a glance
| Generic name | Cellular and tissue based products |
|---|---|
| Also known as | Apligraf, Dermagraft, Epifix, Oasis, Talymed |
| Sponsor | U.S. Wound Registry |
| Drug class | Cellular and tissue-based products |
| Modality | Biologic |
| Therapeutic area | Wound care |
| Phase | Phase 2 |
Mechanism of action
It works by promoting the growth and proliferation of cells and tissues, which helps to repair damaged or diseased areas. This can be particularly useful for treating wounds and other tissue damage.
Approved indications
- Treatment of chronic wounds
Common side effects
- Infection
- Allergic reaction
Key clinical trials
- Phase 1 Study of VELGRAFT, a Living Cellular Construct, in the Management of Chronic Diabetic Foot Ulcers Which Have Attained Granulation Tissue (PHASE1)
- A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation (PHASE2)
- Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904) (PHASE2)
- Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases (PHASE2)
- A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas (PHASE1)
- A Reduced-Intensity Conditioning Regimen (Cyclophosphamide, Pentostatin, Anti-thymocyte Globulin) Followed by Haploidentical Hematopoietic Stem Cell Transplant for the Treatment of Patients With Refractory or Recurrent Severe Aplastic Anemia (PHASE1)
- Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome (PHASE3)
- Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cellular and tissue based products CI brief — competitive landscape report
- Cellular and tissue based products updates RSS · CI watch RSS
- U.S. Wound Registry portfolio CI